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Background:  Globally,  BCG  vaccination  varies  in  efﬁcacy  and  has  some  non-speciﬁc  protective  effects.
Previous  studies  comparing  BCG  strains  have been  small-scale,  with  few or  no immunological  outcomes
and  have  compared  TB-speciﬁc  responses  only.  We  aimed  to evaluate  both  speciﬁc  and  non-speciﬁc
immune  responses  to  different  strains  of BCG  within  a  large  infant  cohort  and  to  evaluate  further  the
relationship  between  BCG  strain,  scarring  and  cytokine  responses.
Methods: Infants  from  the Entebbe  Mother  and  Baby  Study  (ISRCTN32849447)  who  received  BCG-Russia,
BCG-Bulgaria  or BCG-Denmark  at birth, were  analysed  by  BCG strain  group.  At one  year,  interferon-
gamma  (IFN-),  interleukin  (IL)-5,  IL-13  and  IL-10  responses  to  mycobacteria-speciﬁc  antigens  (crude
culture  ﬁltrate  proteins  and  antigen  85)  and  non-mycobacterial  stimuli  (tetanus  toxoid  and  phyto-
haemagglutinin)  were  measured  using  ELISA.  Cytokine  responses,  scar frequency,  BCG  associated  adverse
event  frequency  and  mortality  rates  were  compared  across  groups,  with  adjustments  for potential  con-
founders.
Results:  Both  speciﬁc  and  non-speciﬁc  IFN-, IL-13  and  IL-10  responses  in 1341  infants  differed  between
BCG  strain  groups  including  in  response  to stimulation  with  tetanus  toxoid.  BCG-Denmark  immunised
infants  showed  the highest  cytokine  responses.  The  proportion  of  infants  who  scarred  differed  signif-
icantly,  with  BCG  scars  occurring  in 52.2%,  64.1%  and  92.6%  of  infants  immunised  with  BCG  Russia,
BCG-Bulgaria  and  BCG-Denmark,  respectively  (p  <  0.001).  Scarred  infants  had  higher  IFN- and IL-13
responses  to mycobacterial  antigens  only  than  infants  without  a scar.  The  BCG-Denmark  group  had  the
highest  frequency  of  adverse  events  (p  =  0.025).  Mortality  differences  were  not signiﬁcant.
Conclusions:  Both  speciﬁc  and  non-speciﬁc  immune  responses  to  the  BCG  vaccine  differ  by  strain.  Scarring
after  BCG  vaccination  is  also  strain-dependent  and  is  associated  with  higher  IFN-  and  IL-13 responses
to  mycobacterial  antigens.  The  choice  of  BCG  strain  may  be an important  factor  and  should  be evaluated
when  testing  novel  vaccine  strategies  that  employ  BCG  in  prime–boost  sequences,  or as  a  vector  for  other
vaccine  antigens.
. BackgroundBCG (Bacille Calmette–Guérin), derived from Mycobacterium
ovis in 1926 [1], is the most widely administered vaccine in
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the world, with 90.8% global coverage in 2009 [2]. Several phe-
notypically diverse strains are in use, arising from independent
subculture of attenuated mycobacteria in laboratories across the
world [3–5]. Reported efﬁcacy of BCG has varied considerably, rang-
ing from 0 to 80% [6–8], with tropical countries reporting lower
protection against tuberculosis [8,9]. Several factors that vary with
latitude may  alter BCG potency, including exposure to environmen-
tal mycobacteria [6] and other common infections in the tropics
[10]. Although BCG strain alone cannot account for the extent of
variation in efﬁcacy [8], it may  account for some of the variation
Open access under CC BY license.observed in common clinical and immunological outcomes used in
research, such as BCG scarring and cytokine responses.
The ongoing problem of establishing an accurate immunological
proxy for protection against TB complicates BCG efﬁcacy studies.
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hilst the production of IFN- by CD4+ T cells is vital [20,21], it
s not sufﬁcient, and a more complex picture is emerging involv-
ng multiple cytokines and T cell subsets, including regulatory T
ells [20–24]. Several small human studies have compared immune
esponses to different BCG strains, with variable results [11–19],
ncluding two in Africa, which demonstrated some variability
n T cell proliferation and interferon-gamma (IFN-) production
epending on the strain and route of administration [11–13].
Besides  TB, there is evidence that BCG may  also provide pro-
ection against other illnesses, with studies showing lower rates
f malaria, acute lower respiratory tract infection and overall mor-
ality in BCG-immunised individuals [14,25–27]. Such non-speciﬁc
ffects of BCG have also been demonstrated immunologically, with
ncreased cytokine responses to both BCG-related antigens and
on-BCG antigens such as tetanus toxoid (TT) or phytohaemagglu-
inin (PHA) amongst BCG-immunised children [28,29].
Our  large birth cohort in Entebbe, Uganda, provided an oppor-
unity to examine whether different BCG strains elicited different
mmune responses to both mycobacterial and non-mycobacterial
timuli, and to evaluate further the relationship between BCG
train, scarring and cytokine responses.
. Methods
.1. Study design
The  Entebbe Mother and Baby Study, a randomised double-
lind, placebo-controlled trial of the effect of anthelminthic
reatment on responses to childhood immunisations, has been
escribed elsewhere [10,30–32]; the following methods are rel-
vant to this analysis.
.2.  Recruitment and follow-up
Pregnant  women from the Entebbe peninsula in Uganda were
creened and enrolled at Entebbe Hospital from April 2003 until
ovember 2005. Socio-demographic details were obtained by
uestionnaire during antenatal care. Stool and blood samples were
aken for parasitological and HIV testing and babies of participat-
ng mothers were followed up. Second-born twins, babies who had
ot received all three doses of tetanus vaccine and babies who
ad received their BCG after 6 months or outside Entebbe Hospi-
al (where strain data were unavailable) were excluded from this
nalysis. The HIV status of HIV-exposed infants was  ascertained
hrough PCR of blood taken at age 6 weeks and rapid-test serology
erformed at 18 months.
At  age 12 months infants had blood taken for immunological
nalysis;  anthropometric parameters and the presence and diame-
er of BCG scars were documented. If unwell at the time of the visit,
nfants were treated accordingly and the study investigations were
onducted up to 2 months later. Throughout the study the clinic was
reely accessible as required, with any illnesses or vaccine-related
dverse events being recorded.
.3.  Immunisation
Vaccines were provided by Uganda National Medical Stores.
urses at Entebbe Hospital immunised babies at birth with 0.05 ml
f intradermal BCG over the right deltoid, containing the strain
nd lot available at the time.2 The three strains used during the
tudy period were BCG-Russia (BCG-I strain from Moscow, Serum
nstitute of India, India); BCG-Bulgaria (BCG-SL 222 Soﬁa strain,
2 See supplementary information for BCG lot numbers used.30 (2012) 2083– 2089
BB-NCIPD Ltd., Bulgaria); and BCG-Denmark (BCG-SSI 1331, Statens
Seruminstitut, Denmark). Other vaccines administered were OPV
(at 0, 6, 10 and 14 weeks); DPT, Hib and Hep B (at 6, 10 and 14
weeks); and measles (at 9 months).
2.4. Immunological analysis
Cytokine responses were assessed by six-day whole blood cul-
ture and ELISA assay, as previously described [10]. Cytokine levels
in culture supernatants were measured by ELISA (Beckton Dickin-
son, UK) after stimulation by crude culture ﬁltrate protein, antigen
85 (cCFP, Ag 85; Colorado State University, USA), tetanus toxoid
(TT; Statens Seruminstitut, Denmark) and phytohaemagglutinin
(PHA; Sigma, UK). CFP and Ag85 were used to assess mycobacteria-
speciﬁc immune responses and PHA and TT to assess non-speciﬁc
effects of BCG strains.
IFN- and IL-10 were analysed as representative of type 1 and
regulatory activity respectively. Although IL-4 levels are central
to the type 2 response, IL-5 and IL-13 are more detectable in
supernatants and were therefore measured instead. Results were
adjusted according to responses in unstimulated wells. To avoid
time dependent effects of assay performance, the sequentially col-
lected samples were tested in a randomised order.
2.5. Statistical analysis
Statistical  analyses were conducted using Stata/IC 11.1. Infants
were grouped according to strain of BCG received. Characteris-
tics of the three groups of infants and mothers were compared
using Pearson’s chi-squared test for categorical variables and the
t-test for continuous variables. Cytokine levels below the thresh-
old of detection were set to zero3; distributions of cytokine results
were highly skewed, a recognised phenomenon in immunological
studies [10,30,33]. Cytokine results were therefore transformed to
log10(concentration + 1) before analysis. Mean cytokine responses
were compared between strain groups using random effects linear
regression, anti-logging the regression coefﬁcients to obtain geo-
metric mean ratios (GMRs). Random effects were used to account
for potential between-lot variability (since several lots of vaccine
were administered within each BCG strain group). As some cytokine
results remained skewed after log10 transformation, analyses were
boostrapped [33] with 10,000 repeats to calculate bias-corrected
accelerated conﬁdence intervals. Cytokine responses of infants
with and without a BCG scar were compared using the same meth-
ods but without random effects (being independent of potential
between-lot variability).
Odds  ratios for associations between BCG strain and scar pres-
ence were calculated through random effects logistic regression.
BCG scar sizes were compared across strain groups through linear
regression. Because differences in male and female infant responses
to BCG have been reported [10,14,26,34,35] all analyses were
repeated stratifying by sex, using Wald tests to assess interactions
between the effects of sex and strain.
Consistency of results was  checked between different batches of
assay antigen. The second batches of cCFP and TT appeared to pro-
duce slightly different cytokine responses. The second batch of cCFP
was only used in a small number of samples, which were thereforebatches of TT were of similar size and therefore cytokine responses
to TT were adjusted for TT batch to avoid loss of power.
3 The cut-off points for a positive cytokine response were set to IFN- = 73 pg/ml;
IL-5  = 34 pg/ml; IL-13 = 8 pg/ml; IL-10 = 48 pg/ml (the mean level plus two standard
deviations  of the negative control).
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Table 1
Maternal and infant characteristics according to BCG-strain groups.
BCG-Russia (n = 1124) BCG-Bulgaria (n = 788) BCG-Denmark (n = 169) p-Valueb
Frequency (%)a Frequency (%)a Frequency (%)a
Maternal characteristics
Age  (years)
<20 279 (25%) 183 (23%) 44 (26%)
0.765
20–24  431 (38%) 298 (38%) 55 (33%)
25–29  248 (22%) 184 (23%) 41 (24%)
30–34  108 (10%) 89 (11%) 20 (12%)
≥35 58  (5%) 34 (4%) 9 (5%)
Education (4 missing values)
None  35 (3%) 35 (4%) 5 (3%)
0.748
Primary  579 (52%) 398 (51%) 83 (49%)
Secondary  418 (37%) 287 (37%) 68 (40%)
Tertiary  92 (8%) 65 (8%) 12 (7%)
Tribe  (1 missing value)
Muganda  564 (50%) 388 (49%) 84 (50%)
0.596
Munyankole 98 (9%) 77 (10%) 15 (9%)
Mutoro  43 (4%) 36 (5%) 7 (4%)
Musoga 48  (4%) 27 (3%) 9 (5%)
Luo  71 (6%) 38 (5%) 7 (4%)
Munyawanda 60 (5%) 53 (7%) 5 (3%)
Others  240 (21%) 168 (21%) 42 (25%)
Study  area (28 missing values)
Entebbe 470 (42%) 324 (42%) 62 (37%)
0.093
Kigungu  131 (12%) 83 (11%) 19 (11%)
Manyago,  Kibale 330 (30%) 205 (27%) 46 (27%)
Katabi,  roadside 97 (9%) 92 (12%) 23 (14%)
Katabi,  rural 85 (8%) 68 (9%) 18 (11%)
Household socioeconomic status (40 missing values)
1  (low) 71 (6%) 34 (4%) 10 (6%)
0.323
2 104  (9%) 67 (9%) 13 (8%)
3  347 (31%) 248 (32%) 45 (27%)
4 296  (27%) 241 (31%) 48 (29%)
5  227 (21%) 140 (18%) 41 (25%)
6  (high) 59 (5%) 41 (5%) 9 (5%)
Gravidity
1  303 (27%) 209 (27%) 46 (27%)
0.9332–4  639 (57%) 440 (56%) 93 (55%)
≥5  182 (16%) 139 (18%) 30 (18%)
Malaria  parasitaemia (37 missing values)
Positive 102 (9%) 89 (11%) 22 (13%) 0.197
HIV status
Positive 130 (12%) 94 (12%) 17 (10%) 0.788
Helminth infections (6 missing values)
Hookworm 534 (48%) 302 (38%) 70 (41%) <0.001
Schistosoma mansoni 229 (20%) 136 (17%) 26 (15%) 0.105
Mansonella perstans 232  (21%) 160 (20%) 50 (30%) 0.023
Infant characteristics
Sex
Male  566 (50%) 412 (52%) 90 (53%) 0.617
Age at BCG immunisation (days)
<1 257 (23%) 197 (25%) 38 (22%)
0.274
1–2  647 (58%) 417 (53%) 99 (59%)
3–7  79 (7%) 75 (10%) 11 (7%)
8–28  81 (7%) 57 (7%) 16 (9%)
29–6  months 60 (5%) 42 (5%) 5 (3%)
Malaria  parasitaemia at 1 year (655 missing values)c
Positive 53 (7%) 18 (3%) 9 (7%) 0.033
HIV status at 1 year (43 missing values)c,d
Positive 24 (2%) 21 (3%) 6 (4%) 0.478
Mean (±SD) Mean (±SD) Mean (±SD)
Birth  weight (326 missing values) (kg) 3.186 (±0.476) 3.171 (±0.495) 3.179 (±0.462) 0.827
Lymphocyte count at 1 year (544 missing values)c (cells per 109/l) 6.927 (±2.683) 6.870 (±2.607) 6.625 (±2.414) 0.474
p-Values <0.05 are indicated in bold.
a indicates crude frequencies and proportions (%) of each variable outcome within each BCG strain group, unless otherwise indicated.
b p-Value for test of null hypothesis that there is no association between characteristic and BCG strain group.
d to b
t
t
tc Data are only available for infants who attended the study clinic at 1 year.
d Babies were assumed to be HIV-negative if their mothers were HIV-negative, anAs different strains were administered during set periods of
ime in sequence according to their availability, there was  poten-
ial for confounding by factors associated with both calendar
ime and cytokine responses (Table 1) [10]. Factors considered ase HIV positive at one year if serological results were positive at age 18 months.a priori confounders were infant malaria parasitaemia, maternal
Mansonella perstans and hookworm infection, and area of resi-
dence (as the recruitment area was gradually expanded to include
more rural areas surrounding Entebbe and different environmental
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xposures may  inﬂuence cytokine responses). All analyses were
djusted for the above factors as well as HIV infection, which
auses severe restriction of infant cytokine responses [10,36]. As
nthelminthic treatment allocation was randomised and was found
o have no effect on infant immune responses [30], maternal
nthelminthic was not considered as a possible confounder, or
djusted for, in this analysis.
Mortality  rates per 1000 person years were compared between
train groups using Cox regression hazard ratios. The numbers of
CG-related adverse events were tabulated by group and compared
sing Fisher’s exact test.
.6.  Ethics statement
All  mothers gave informed, written consent. Ethical approval
or the trial was granted from the Science and Ethics Committee of
he Uganda Virus Research Institute, Uganda National Council for
cience and Technology, and London School of Hygiene and Tropical
edicine.
. Results
.1. Participants
Of  2345 livebirths, 2081 singleton babies received BCG at
ntebbe Hospital within 6 months of birth. Of these, 145 infants
id not have data on immunisations other than those administered
t birth; 220 infants did not receive all three doses of tetanus tox-
id; 60 infants died or were lost to follow-up before 1 year of age;
15 infants were still in follow-up but did not provide a blood sam-
le within the speciﬁed time frame. Therefore 1341 samples with
mmunological results were eligible for this analysis. Mothers of
nfants not included were in earlier stages of gestation at recruit-
ent, younger, and more likely to be ﬁrst-time mothers, of lower
ocio-economic status and living in a more distant study area [30].
owever, lack of eligibility was not associated with strain group.
The  three groups had similar socio-demographic characteristics
Table 1); there were however differences in maternal hookworm
nd M.  perstans infection prevalence. Amongst infants, there were
o signiﬁcant differences in sex ratio, birth weights, HIV status
r mean lymphocyte counts; but malaria parasitaemia differed
etween groups.
.2.  Cytokine responses and scar frequency
Cytokine responses to both mycobacteria-speciﬁc (cCFP and
g85) and non-speciﬁc stimuli (TT and PHA) differed between BCG
trains (Table 2). In particular, the BCG-Denmark group demon-
trated IFN- responses that were signiﬁcantly higher than those
f the BCG-Russia group to all four stimuli, as well as higher
L-13 responses to cCFP and PHA. Compared to BCG-Russia, IL-5
esponses did not differ in the BCG-Denmark group. However in
he BCG-Bulgaria group, they were marginally lower in response
o speciﬁc antigens. IL-10 levels were notably higher for both
CG-Bulgaria and BCG-Denmark groups relative to BCG-Russia in
esponse to all stimuli.
Overall,  59.0% of the one-year olds had a BCG scar. There were
igniﬁcant differences between the proportions of each group who
ad a BCG scar: BCG-Denmark had a markedly higher association
ith scarring than BCG-Russia or BCG-Bulgaria (p < 0.001; Table 2).
CG scar size did not signiﬁcantly differ between groups (data not
hown).The above observations were similar after stratifying by infant
ex. For cCFP, Ag85 and PHA there was a tendency for some effects
f BCG strain to appear stronger in female infants (data not shown).
n response to TT, there was an interaction between sex and strain30 (2012) 2083– 2089
for  IL-10 responses (Table 3), with stronger associations amongst
female infants. However, similar proportions of girls and boys
developed a scar.
Samples  from infants with BCG scars demonstrated higher IFN-
 and IL-13 responses to mycobacterial antigens, but not to TT or
PHA, than those without a scar (Table 4). There were no differences
in IL-5 or IL-10 responses by scar status for any stimulus.
3.3. BCG-related adverse events and mortality from all causes
BCG-related adverse events included 2 ulcers and 12 abscesses,
occurring in 0.3% of the BCG-Russia group, 1.0% of the BCG-Bulgaria
group and 1.8% of the BCG-Denmark group (p = 0.025). Observed
mortality appeared slightly higher in the BCG-Denmark group,
however the study was underpowered to detect signiﬁcant differ-
ences (Table 5).
4.  Discussion
This infant cohort in a low-resource tropical country, recruited
before birth and followed up prospectively, provided a good oppor-
tunity to investigate potential differences between the effects of
three BCG strains that are commonly used globally. We  found
signiﬁcant differences in mycobacteria-speciﬁc and non-speciﬁc
immune responses, and in the frequency of BCG-associated adverse
events, according to the vaccine strain used. To our knowledge, this
is the largest study to evaluate the effects of BCG strain on immune
responses to the BCG vaccine and the only study to assess both
speciﬁc and non-speciﬁc responses [11].
Other studies have shown that BCG elicits type 1 and type 2
responses, to both mycobacteria-speciﬁc and non-speciﬁc stimuli
[28,29]. Non-speciﬁc effects have also been reported at the clinical
level, with reductions in non-TB infections and in overall mortality
in BCG immunised infants [14,25–27,35,36]. Furthermore, BCG has
been shown to act non-speciﬁcally as a primer for other vaccines
[29]. Here we  were able to conduct a broad analysis of the effect of
BCG strain by comparing type 1 (IFN-), type 2 (IL-5 and IL-13) and
regulatory (IL-10) responses to both mycobacteria-speciﬁc (cCFP
and Ag85) and non-speciﬁc (TT and PHA) stimuli.
The results revealed three signiﬁcant patterns of strain-
dependent variability of immune responses to both mycobacteria-
speciﬁc and non-speciﬁc stimuli: higher IFN- and IL-13 responses
in the BCG-Denmark group; lower IL-5 responses in the
BCG-Bulgaria group; and higher IL-10 responses in both the
BCG-Denmark and BCG-Bulgaria group compared to BCG-Russia.
Consistent with being at the greatest genetic distance from the
other two  strains [9], the cytokine responses of the BCG-Denmark
group were the most divergent. Surprisingly however, they were
also the highest overall, despite being most distantly related to the
original M. bovis strain [37]. It is also interesting that BCG-Bulgaria
and BCG-Russia behaved slightly differently in this cohort, despite
being genetically identical, except for possible single nucleotide
changes [38]. As all infants were immunised with BCG, it is uncer-
tain how these ﬁndings would relate to non-speciﬁc responses
(such as the response to TT) amongst BCG-unvaccinated infants,
however, differences between strains in non-speciﬁc effects were
clearly demonstrated.
It  is possible that the greater immunogenicity of BCG-Denmark
may lead to better protection against TB. However, IFN- alone
is an insufﬁcient protective marker and it is feasible that higher
regulatory IL-10 production in the same group may counteract
its effects [39]. The observation that IL-10 production differed
between strains is contrary to a recent study [28] that found that
BCG did not stimulate an IL-10 response. This analysis suggests
that the ability of BCG to stimulate an IL-10 response may  be
E.J. Anderson et al. / Vaccine 30 (2012) 2083– 2089 2087
Table 2
Effect of BCG strain on cytokine responses and scar frequency.
Cytokine Assay stimulus Russia (n = 719) Bulgaria (n = 508) Denmark (n = 114)
Geometric
mean (pcg/ml)
Geometric
mean (pcg/ml)
GMRa (95% CI) Geometric
mean (pcg/ml)
GMRa (95% CI)
IFN-
cCFPb 261.9 262.8 0.96 (0.61, 2.04) 622.3 2.24 (1.42, 4.00)
Ag85 130.9 113.3 0.80 (0.46, 1.32) 278.3 2.01 (1.38, 2.69)
TTc 28.5 31.9 0.96 (0.46, 2.04) 82.6 2.41 (1.14, 4.85)
PHA 281.2 299.3 1.00 (0.62, 1.66) 891.4 3.09 (2.11, 5.71)
IL-5
cCFPb 4.4 3.3 0.70 (0.23, 0.98) 5.2 1.13 (0.81, 1.66)
Ag85 2.5 2.2 0.83 (0.71, 0.99) 3.0 1.15 (0.48, 1.82)
TTc 11.1 9.1 0.61 (0.23, 1.34) 16.3 0.92 (0.34, 2.19)
PHA 43.3 28.5 0.61 (0.35, 1.04) 93.1 2.01 (0.98, 3.81)
IL-13
cCFPb 19.4 14.4 0.74 (0.35, 1.32) 30.7 1.51 (1.14, 2.43)
Ag85 7.7 6.5 0.81 (0.52, 1.08) 10.4 1.27 (0.54, 2.02)
TTc 43.1 32.0 0.69 (0.31, 1.51) 51.3 0.95 (0.38, 2.02)
PHA 140.4 137.5 0.96 (0.60, 1.81) 342.5 2.28 (1.55, 4.14)
IL-10
cCFPb 56.3 119.7 2.17 (1.48, 4.03) 234.3 4.16 (2.85, 6.89)
Ag85 49.1 103.4 2.06 (1.27, 2.82) 78.3 1.52 (1.10, 2.21)
TTc 3.3 8.6 2.17 (1.33, 8.67) 10.3 2.59 (1.39, 6.08)
PHA 125.7 203.8 1.53 (0.99, 2.38) 360.3 2.79 (2.10, 4.24)
Russia (n = 719) Bulgaria (n = 508) Denmark (n = 114)
BCG scar frequency (%) BCG scar frequency (%) Scar presence OR (95% CI) BCG scar frequency (%) Scar presence OR (95% CI)
352 (49.0%) 333 (65.6%) 1.84 (1.25, 2.71) 106 (92.3%) 14.28 (5.85, 34.85)
The table shows strain-speciﬁc mean cytokine responses (IFN-, IL-5, IL-13 and IL-10) to four assay stimuli: culture ﬁltrate protein (cCFP); antigen 85 (Ag85); tetanus toxoid
(TT);  and phytohaemagglutinin (PHA). Scar frequencies and proportions (%) for each BCG-strain group are also included as well as odds ratios (ORs) for scar presence. Missing
values for cCFPb, Ag85, TT and PHA assays are 252, 1, 7 and 15 respectively.
a Geometric mean ratios (GMRs) comparing responses in infants vaccinated with BCG-Bulgaria or BCG-Denmark versus BCG-Russia, with bias-corrected accelerated
conﬁdence intervals. These are adjusted for: study area, infant malaria parasitaemia, infant HIV status, maternal M.  perstans infection and maternal hookworm infection (at
1  year). A random effects model was applied to the regression calculations to allow for clustering within BCG lot groups. GMRs and ORs signiﬁcantly different from 1.00 are
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indicated in bold.
b Excluding the 2nd batch of cfp antigen (see text).
c Adjusted for tetanus toxoid batch (see text).
train-dependent, although a study that compared BCG-Denmark
o BCG-Brazil and BCG-Japan, found no such differences [16].
mportantly, the differences across groups were observed in
esponse to TT and PHA as well as to mycobacterial antigens,
uggesting that the non-speciﬁc effects of BCG immunisation
able 3
ex-stratiﬁed effect of BCG strain on cytokine responses to tetanus toxoid (TT) and BCG s
Cytokine Sex (M/F) Russia (n = 719) Bulgaria (n = 508) 
Geometric
mean (pcg/ml)
Geometric
mean (pcg/ml)
GM
IFN-
M 34.2 1.04 0.9
F  23.9 25.23 0.8
IL-5
M  12.3 11.63 0.6
F  10.0 6.94 0.5
IL-13
M  46.1 38.29 0.6
F  40.4 26.28 0.6
IL-10
M  4.1 9.59 1.
F  2.7 7.70 2.
Sex  (M/F) Russia (n = 719) Bulgaria (n = 508) 
BCG scar frequency (%) BCG scar frequency (%) Scar presence OR
M 182 (51.9%) 173 (65.3%) 1.64 (1.04, 2.60) 
F 170 (46.3%) 160 (65.8%) 2.18 (1.36, 3.49) 
he table shows strain-speciﬁc cytokine responses (IFN-, IL-5, IL-13 and IL-10) to tetanu
ex.  There are 6 missing values (3 males and 3 females). Sex did not signiﬁcantly interact
a Geometric mean ratios (GMRs) comparing responses in infants vaccinated with BC
onﬁdence intervals. These are adjusted for: study area, malaria parasitaemia, HIV status
as  applied to the regression calculations to allow for clustering within BCG lot groups
ndicated in bold.
b p-Value for test of null hypothesis that there is no interaction of sex with the effect of
c p-Value for test of null hypothesis that there is no interaction of sex with the effect ofare  likely to be dependent on the strain administered. The
ﬁnding for TT speciﬁcally indicates that BCG strain differences
can modulate the infant response to subsequent, unrelated
exposures to antigens, including vaccines (and presumably,
pathogens).
car frequency.
Denmark (n = 114) Interaction
p-valueb
Ra (95% CI) Geometric
mean (pcg/ml)
GMRa (95% CI)
7 (0.53, 1.77) 59.2 1.31 (0.47, 3.63)
0.0838 (0.47, 1.66) 115.3 4.14 (1.47, 11.61)
4 (0.37, 1.13) 13.6 0.60 (0.23, 1.54)
0.2017 (0.32, 1.01) 19.7 1.35 (0.52, 3.48)
9 (0.42, 1.16) 35.1 0.50 (0.21, 1.19)
0.0567 (0.39, 1.13) 74.9 1.74 (0.73, 4.13)
74 (1.09, 2.78) 6.7 1.08 (0.49, 2.37)
0.0173 (1.71, 4.36) 15.9 6.73 (3.13, 14.45)
Denmark (n = 114) p-Valuec
 (95% CI) BCG scar frequency (%) Scar presence OR (95% CI)
53 (93.0%) 12.40 (3.85, 39.96)
0.55753 (93.0%) 16.43 (5.12, 52.74)
s toxoid (TT) antigen and BCG scar frequency in each BCG strain group, stratiﬁed by
 with cytokine responses to cCFP, Ag85 or PHA (data not shown).
G-Bulgaria or BCG-Denmark versus BCG-Russia, with bias-corrected accelerated
, M. perstans infection and hookworm infection (at 1 year). A random effects model
. GMRs and ORs signiﬁcantly different from 1.00 and p-values that are <0.05 are
 strain on cytokine responses to tetanus toxoid.
 strain on BCG scar frequency.
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Table 4
Relationship between cytokine responses and BCG scar presence.
Cytokine Assay stimulus Absent scar (n = 549) Present scar (n = 791)
Geometric mean (pcg/ml) Geometric mean (pcg/ml) GMRa (95% CI)
IFN-
cCFPb 214.4 339.9 1.59 (1.21, 2.10)
Ag85 92.0 170.1 1.85 (1.43, 2.42)
TTc 27.9 36.3 1.24 (0.92, 1.68)
PHA 302.1 328.1 1.09 (0.87, 1.36)
IL-5
cCFPb 3.8 4.4 1.17 (0.91, 1.50)
Ag85 2.2 2.5 1.15 (0.95, 1.39)
TTc 37.2 41.0 1.10 (0.83, 1.47)
PHA 9.8 11.2 1.11 (0.84, 1.48)
IL-13
cCFPb 14.0 22.8 1.63 (1.26, 2.10)
Ag85 5.9 8.7 1.46 (1.17, 1.82)
TTc 39.2 38.9 0.97 (0.76, 1.26)
PHA 141.6 156.2 1.10 (0.91, 1.36)
IL-10
cCFPb 75.3 77.2 1.02 (0.82, 1.29)
Ag85 64.2 70.4 1.10 (0.89, 1.35)
TTc 5.0 5.5 1.00 (0.79, 1.26)
PHA 160.5 168.0 1.05 (0.87, 1.26)
The table compares the cytokine responses of infants, with and without BCG scars, to four assay stimuli: crude culture ﬁltrate protein (cCFP); antigen 85 (Ag85); tetanus
toxoid (TT); and phytohaemagglutinin (PHA). Missing values for cCFPb, Ag85, TT and PHA assays are 253, 2, 8 and 16 respectively.
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There was striking disparity in BCG scar frequency between
roups, with an almost two-fold increase in scarring frequency
n the BCG-Denmark group compared to the BCG-Russia group.
he overall proportion with scars was 59%, despite 100% immu-
isation coverage at birth. This is much lower than observed scar
revalence in other populations [25,27,28,40] and is unlikely to
e attributable to poor immunisation technique considering that
3% of the BCG-Denmark group developed a scar (p < 0.001). This
nalysis may  be evidence that the association between BCG scar
requency and immunisation status is strain-dependent. BCG scars
ave often been used in research to identify BCG immunised indi-
iduals, which may  be a valid method in a population uniformly
mmunised with one strain, such as BCG-Denmark, which causes
he majority of vaccinees to scar. However, in populations immu-
ised with a strain that causes fewer scars, scarring may  reﬂect an
ndividual’s immune response to the vaccine rather than immu-
isation status, leading to many misclassiﬁcations. In countries
sing multiple strains, identifying individuals by scar status may
ive results reﬂecting the effects of one strain and not the whole
mmunised population. Although correlations between scar size
nd cytokine responses have been demonstrated at 4 years of age
28], it is unsurprising that no relationship was shown here, as BCG
cars are still very small at one year.
Studies in Guinea Bissau have demonstrated an association
etween scar development after BCG immunisation and beneﬁt-
ng from its non-speciﬁc effects [14,25–27]. However, our results
how no correlation between scarring and non-speciﬁc cytokine
esponses, with only higher mycobacteria-speciﬁc IFN- and IL-13
esponses differentiating those with a scar from those without. BCG
train did inﬂuence both non-speciﬁc immune responses and scar
evelopment, suggesting that BCG strain could be a confounder
n the relationship between scarring and non-speciﬁc responses.
or example, the BCG-Denmark strain caused both higher
able 5
ffect  of BCG strain on mortality.
BCG strain group Number of deaths from all causes Rate per 1
Russia (n = 1124) 22 20.5 (13.5
Bulgaria  (n = 788) 14 18.6 (11.0
Denmark (n = 169) 4 25.0 (9.4, n with bias-corrected accelerated conﬁdence intervals. GMRs signiﬁcantly different
IFN-  responses to non-speciﬁc stimuli and also a greater frequency
of scarring. The infants’ sex modiﬁed the effect of BCG strain on
responses to tetanus toxoid, but not to either mycobacteria-speciﬁc
antigen. This ﬁnding is in keeping with reports that girls may
experience more non-speciﬁc BCG effects than boys [14,26,35,36]
although a mechanism for this phenomenon has not been estab-
lished [36].
This  study was underpowered to detect differences in mortal-
ity. However, signiﬁcant differences were detected between the
proportions of each group that experienced an adverse event, the
highest of which occurred in the BCG-Denmark group. As BCG-
Denmark stimulated the highest cytokine responses, it is possible
that there may  be a trade-off between immunogenicity and adverse
event induction, although the small number of events warrants
caution in interpreting this relationship.
Our results emphasise the importance of identifying and adjust-
ing for the strain of BCG used in studies of vaccine efﬁcacy, or of
correlates of protection, whenever BCG is employed as part of a vac-
cination strategy. This includes studies evaluating novel vaccines
that employ a prime–boost strategy, as the choice of priming BCG
strain may  inﬂuence the results. Our data also suggests that BCG
strain may  inﬂuence outcomes when employing BCG as a vector for
vaccines against other pathogens. Importantly, the choice of BCG
strain may  have clinical effects beyond the protection against TB.
Further large-scale comparative investigation of BCG strains with
clinical primary outcomes would be valuable.
This analysis was  not part of our original trial design, so infants
were not randomised to receive different BCG strains. This may
have led to potential confounders, for example, due to different
seasonal exposures to infections, which we could not account for.
However, we did identify differences in maternal helminth and
infant malaria status between the groups and we adjusted for these
variables in the analysis; adjusted results were similar to crude
000 person years (95% CI) Hazard ratio (95% CI) p-Value
, 31.1) 1
0.87, 31.4) 0.91 (0.46, 1.77)
66.7) 1.22 (0.42, 3.53)
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ndings. One-year olds were appropriate subjects as it has been
hown that IFN-, IL-5, IL-13 and IL-10 responses to BCG given at
irth are detectable at one year with some effects waning by two
ears [28]. However, it was not possible to analyse TB outcomes
r long-term effects. Further work will include a repeated analy-
is of the same cohort at ﬁve years, assessing TB prevalence and
ncidence as well as non-TB illnesses and overall mortality. This
ay provide the warranted longitudinal evidence of whether or
ot strain-dependent effects observed at the molecular level trans-
ate to clinical outcomes in this cohort. In the meantime, whenever
ultiple BCG strains are used in future research, or when the effects
f BCG or other immunisation regimes are compared in different
opulations, accounting for BCG strain is vital.
cknowledgements
We thank the participants and staff of the Entebbe Mother
nd Baby Study, the midwives of the Entebbe Hospital Maternity
epartment, and the staff of the Clinical Diagnostic Services Labo-
atory at the MRC/UVRI Uganda Research Unit on AIDS. We thank
r Miliana Chouchkova of BB-NCIPD Ltd., Bulgaria and Mr  S.M. Dod-
adkar of Serum Institute of India, India, for providing information
n the BCG strains provided by their institutions.
Conﬂict of interest statement: The authors of this paper do not
ave any commercial or other associations that may  pose a conﬂict
f interest. Funding: This work was supported by Wellcome Trust
grant numbers 064693, 079110]. Emily L. Webb was supported
y the UK Medical Research Council. Mycobacterial antigens were
rovided through the National Institutes of Health [contract NOI-
I-25147].
ppendix A. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at doi:10.1016/j.vaccine.2012.01.053.
eferences
[1] Calmette A, Guérin C, Boquet A, Négre L. Sur la vaccination préventive des
enfants  nouveaux-nés contre la tuberculose par le BCG. Ann Inst Pasteur
1927;41:201–31.
[2]  WHO-UNICEF Estimates of BCG Coverage. Data Source: WHO  Vaccine-
preventable Diseases: Monitoring System 2010 Global Summary. Available at:
http://apps.who.int/immunization monitoring/en/globalsummary/timeseries/
tswucoveragebcg.htm [accessed 16.04.2011].
[3]  Behr MA, Small MA.  A historical and molecular phylogeny of BCG strains. Vac-
cine  1999;17:915–22.
[4] Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W,  Valenti P, et al. Genome
plasticity  of BCG and impact on vaccine efﬁcacy. PNAS 2007;104(13):5596–601.
[5]  Ritz N, Curtis N. Mapping the global use of different BCG vaccine strains. Tuber-
culosis  2009;89:248–51.
[6] Brewer TF. Preventing tuberculosis with Bacillus Calmette–Guérin vaccine: a
meta-analysis  of the literature. CID 2000;31(3):S64–7.
[7]  Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME,  Burdick E, et al.
The  efﬁcacy of bacillus Calmette–Guerin vaccination of newborns and infants
in  the prevention of tuberculosis: meta-analyses of the published literature.
Pediatrics  1995;96(1):29–35.
[8] Fine PE. Variation in protection by BCG: implications of and for heterologous
immunity. Lancet 1995;346(8986):1339–45.
[9] Wilson ME,  Fineberg HV, Colditz GA. Geographic latitude and the efﬁcacy of
Bacillus  Calmette–Guerin vaccine. CID 1995;20:982–91.
10] Elliott AM,  Mawaa PA, Webb EL, Nampijjaa M.  Effects of maternal and infant
co-infections,  and of maternal immunisation, on the infant response to BCG
and  tetanus immunization. Vaccine 2011;29:247–55.
11]  Ritz N, Hanekom WA,  Robins-Browne R, Britton WJ,  Curtis N. Inﬂuence of BCG
vaccine  strain on the immune response and protection against tuberculosis.
FEMS  Microbiol Rev 2008;32:821–41.
12] Davids V, Hanekom WA,  Mansoor N, Gamieldien H, Gelderbloem SJ, Hawkridge
A,  et al. The effect of Bacille Calmette–Guerin vaccine strain and route
of  administration on induced immune responses in vaccinated infants. JID
2006;193:531–6.
13]  Hussey GD, Watkins MLV, Goddard EA, Gottschalk S, Hughes EJ, Iloni K,
et  al. Neonatal mycobacterial speciﬁc cytotoxic T-lymphocyte and cytokine
[
[30 (2012) 2083– 2089 2089
proﬁles in response to distinct BCG vaccination strategies. Immunology
2002;105:314–24.
14]  Roth A, Sodemann M,  Jensen H, Poulsen A, Gustafson P, Weise C, et al. Tuberculin
reaction,  BCG scar, and lower female mortality. Epidemiology 2006;17:562–8.
15] Guerin N, Teulieres L, Noba A, Schlumberger M,  Bregère P, Chauvin P. Com-
parison  of the safety and immunogenicity of the lyophilized Merieux seed and
the  World Health Organization working reference BCG vaccines in school-aged
children  in Senegal. Vaccine 2009;17:105–9.
16] Wu B, Huang C, Garcia L, Ponce de Leon A, Sifuentes Osornio J, Bobadilla-
del-Valle M,  et al. Unique gene expression proﬁles in infants vaccinated with
different  strains of Mycobacterium bovis Bacille Calmette–Guerin. Infect Immun
2007;75:3658–64.
17]  Gorak-Stolinska P, Weir RE, Floyd S, Lalor MK, Stenson S, Branson K, et al.
Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with
Glaxo-Evans  1077 BCG vaccine. Vaccine 2006;24:5726–33.
18] Hoft DF, Kemp EB, Marinaro M,  Cruz O, Kiyono H, McGhee JR, et al. A double-
blind,  placebo-controlled study of Mycobacterium-speciﬁc human immune
responses  induced by intradermal Bacille Calmette–Guerin vaccination. J Lab
Clin  Med 1999;134:244–52.
19] Aronson NE, Santosham M, Comstock GW,  Howard RS, Moulton LH,  Rhoades
ER,  et al. Long-term efﬁcacy of BCG vaccine in American Indians and Alaska
Natives:  a 60-year follow-up study. JAMA 2004;291:2086–91.
20]  Walzl G, Ronacher K, Hanekom W,  Scriba TJ, Zumla A. Immunological biomark-
ers  of tuberculosis. Nat Rev Immunol 2011;11:343–54.
21]  Dietrich J, Doherty M.  Interaction of Mycobacterium tuberculosis with the host:
consequences  for vaccine development. APMIS 2009;117:440–57.
22] Soares AP, Scriba TJ, Joseph S, Harbacheuski R, Murray RA, Gelderbloem SJ, et al.
Bacillus  Calmette–Guérin vaccination of human newborns induces T cells with
complex  cytokine and phenotypic proﬁles. J Immunol 2008;180:3569–77.
23] Mittrucker H-W, Steinhoff U, Kohler K, Krause M,  Lazar D, Mex  P, et al. Poor
correlation  between BCG vaccination-induced T cell responses and protection
against  tuberculosis. PNAS 2007;104(30):12434–9.
24] Kagina BM,  Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, et al. Speciﬁc T
cell  frequency and cytokine expression proﬁle do not correlate with protection
against  tuberculosis after bacillus Calmette–Guérin vaccination of newborns.
Am  J Respir Crit Care Med  2010;182(8):1073–9.
25] Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow
up  study in Guinea-Bissau, West Africa. BMJ 2000;321:1435–8.
26] Stensballe LG, Nantea E, Jensen IP, Kofoed P-E, Poulsen A, Jensen H,  et al. Acute
lower  respiratory tract infections and respiratory syncytial virus in infants
in  Guinea-Bissau: a beneﬁcial effect of BCG vaccination for girls: community
based  case–control study. Vaccine 2005;23:1251–7.
27]  Roth A, Gustafson P, Nhaga A, Djana Q, Poulsen A, Garly ML,  et al. BCG vac-
cination  scar associated with better childhood survival in Guinea-Bissau. Int J
Epidemiol  2005;34:540–7.
28] Djuardi Y, Sartono E, Wibowo H, Supali T, Yazdanbakhsh M. A longitudinal study
of  BCG vaccination in early childhood: the development of innate and adaptive
immune  responses. PLoS One 2010;5(11):e14066.
29] Ota MOC, Vekemans J, Schlegel-Haueter SE, Fielding K. Inﬂuence of Mycobac-
terium  bovis Bacillus Calmette–Guérin on antibody and cytokine responses to
human  neonatal vaccination. J Immunol 2002;168:919–25.
30] Webb EL, Mawa PA, Ndibazza J, Kizito D, Namatovu A, Kyosiimire-Lugemwa
J, et al. Effect of single-dose anthelmintic treatment during pregnancy on
an  infant’s response to immunisation and on susceptibility to infectious dis-
eases  in infancy: a randomised, double-blind, placebo-controlled trial. Lancet
2011;377:52–62.
31]  Ndibazza J, Muhangi L, Akishule D, Kiggundu M,  Ameke C1 Oweka J. Effects of
deworming  during pregnancy on maternal and perinatal outcomes in Entebbe,
Uganda:  a randomized controlled trial. CID 2010;50:531–40.
32]  Elliott AM,  Kizza M,  Quigley MA,  Ndibazza J, Nampijja M,  Muhangi L, et al. The
impact  of helminths on the response to immunization and on the incidence of
infection  and disease in childhood in Uganda: design of a randomized, double-
blind,  placebo-controlled, factorial trial of deworming interventions delivered
in  pregnancy and early childhood. Clin Trials 2007;4:42–57.
33] McGuinness D, Bennett S, Riley E. Statistical analysis of highly skewed immune
response  data. J Immunol Methods 1997;201(1):99–114.
34]  Aaby P, Jensen H, Rodrigues A, Garly M-L, Stabell Benn C, Maria Lisse I, et al.
Divergent  female–male mortality ratios associated with different routine vac-
cinations  among female–male twin pairs. Int J Epidemiol 2004;33:367–73.
35] Flanagan KL, Klein SL, Skakkebaek NE, Marriott I, Marchant A, Selin L, et al. Sex
differences  in the vaccine-speciﬁc and non-targeted effects of vaccines. Vaccine
2011;29:  2349–54.
36] Elliott AM,  Hurst TJ, Balyeku MN,  Quigley MA,  Kaleebu P, French N, et al. The
immune  response to Mycobacterium tuberculosis in HIV-infected and unin-
fected  adults in Uganda: application of a whole blood cytokine assay in an
epidemiological study. Int J Tuberc Lung Dis 1999;3(3):239–47.
37] Keller PM, Boettger EC, Sander P. Tuberculosis vaccine strain Mycobac-
terium  bovis BCG Russia is a natural recA mutant. BMC  Microbiol 2008;8:
120.
38]  Stefanova T, Chouchkova M,  Hinds J, Butcher PD, Inwald J, Dale J, et al. Genetic
composition  of Mycobacterium bovis BCG substrain Soﬁa. J Clin Microbiol39]  Redford PS, Murray PJ, O’Garra A. The role of IL-10 in immune regulation during
M.  tuberculosis infection. Mucosal Immunol 2011;4(3):261–70.
40] Hong YP, Kim SJ, Lew WJ,  Lee EK, Han YC. The seventh nationwide tuberculosis
prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 1998;2(1):27–36.
